Scientific Reviews
Product Guides
Blogs
Topics
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!2025-02-06
23 Results for "
BRK
" in MedChemExpress (MCE) Product Catalog:
Products (23)
23 Results for "BRK" in MCE Product Catalog:
4
4 Cited Publications
Target:
Research Areas:
SB-633825 is a potent and ATP-competitive inhibitor of TIE2, LOK (STK10) and BRK with IC50s of 3.5 nM, 66 nM, 150 nM, respectively. SB-633825 can inhibit cancer cell growth and angiogenesis .
Tilfrinib (compound 4f) is a potent and selective Brk/PTK6 inhibitor with an IC50 value of 3.15 nM for Brk. Tilfrinib shows good anti-proliferative activity and has potential of anti-tumour .
Cat. No.: HY-171830
CAS No.: 2408339-39-7
Synonyms: YX39-105
Target:
Research Areas:
MS105 (YX39-105) is an orally active and selective protein tyrosine kinase 6 (PTK6) (BRK) PROTAC degrader. MS105 recruits VHL E3 ligase via a VHL ligand moiety, promotes PTK6 ubiquitination and proteasomal degradation, inhibits the proliferation and migration of breast cancer cells, and induces apoptosis. MS105 shows potential for use in breast cancer research .
Cat. No.: HY-115514A
CAS No.: 2250025-98-8
BRK inhibitor P21d hydrochloride is a potent breast tumor kinase (BRK/PTK6) inhibitor with an IC50 of 30 nM. BRK inhibitor P21d hydrochloride inhibits p-SAM68 with an IC50 of 52 nM. BRK inhibitor P21d hydrochloride can be used to evaluate the in vivo activity of BRK inhibitors in xenograft breast tumor models .
XMU-MP-2 is a selective BRK/PTK6 inhibitor with an IC50 of 5.4 nM. XMU-MP-2 inhibits the proliferation of BRK-positive breast cancer cells and induces apoptosis. XMU-MP-2 is applicable to breast cancer-related research .
Cat. No.: HY-178460
BRK/PTK6-IN-1 (Compound 51) is a highly efficient and selective BRK inhibitor (IC50 = 3.37 nM, Kd = 44 nM). BRK/PTK6-IN-1 can reduce MMP-9 protein expression and inhibit IGF-1 induced AKT phosphorylation in MDA-MB-231 cells. BRK/PTK6-IN-1 significantly inhibits migration, invasion, and colony formation but does not affect cell proliferation. BRK/PTK6-IN-1 is often used in the research of breast cancer and other cancers .
Cat. No.: HY-RS11403
Target:
Research Areas:
PTK6 Human Pre-designed siRNA Set A contains three designed siRNAs for PTK6 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.
Cat. No.: HY-RS01625
Target:
Research Areas:
BRK1 Human Pre-designed siRNA Set A contains three designed siRNAs for BRK1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.
Cat. No.: HY-155227S
CAS No.: 2730429-93-1
Cat. No.: HY-123597
CAS No.: 15427-93-7
Synonyms: DDUG; NCI C04808
Target:
Research Areas:
NSC 109555 is an ATP-competitive inhibitor of checkpoint kinase 2 (Chk2; IC50=200 nM in a cell-free kinase assay). It is selective for Chk2 over Chk1 and 16 kinases in a panel but does inhibit Brk, c-Met, IGFR, and LCK with IC50 values of 210, 6,000, 7,400, and 7,100 nM, respectively. NSC 109555 inhibits Chk2 autophosphorylation and phosphorylation of the Chk2 substrate histone H1 in vitro (IC50=240 nM). It inhibits the growth of, and induces autophagy in, L1210 leukemia cells in vitro.2 NSC 109555 (1,250 nM) potentiates gemcitabine-induced cytotoxicity in MIA PaCa-2, CFPAC-1, PANC-1, and BxPC-3 pancreatic cancer cells, as well as reduces gemcitabine-induced increases in Chk2 phosphorylation and enhances gemcitabine-induced production of reactive oxygen species (ROS) in MIA PaCa-2 cells.
Cat. No.: HY-P84558A
Synonyms: BRK; FLJ42088
Cat. No.: HY-P702726
Purity: ≥ 80%, as determined by reducing SDS-PAGE.
Synonyms: PTK6; PTK6 protein tyrosine kinase 6; protein-tyrosine kinase 6; BRK; breast tumor kinase; protein-tyrosine kinase BRK; tyrosine-protein kinase BRK; FLJ42088;
Species:
Source:
Cat. No.: HY-P81458A
Synonyms: PTK6; BRK; Protein-tyrosine kinase 6; Breast tumor kinase; Tyrosine-protein kinase BRK
Cat. No.: HY-108333R
CAS No.: 956613-01-7
Target:
Research Areas:
SB-633825 (Standard) is the analytical standard of SB-633825 (HY-108333). This product is intended for research and analytical applications. SB-633825 is a potent and ATP-competitive inhibitor of TIE2, LOK (STK10) and BRK with IC50s of 3.5 nM, 66 nM, 150 nM, respectively. SB-633825 can inhibit cancer cell growth and angiogenesis .
Cat. No.: HY-P72856
Purity: ≥ 90%, as determined by reducing SDS-PAGE.
Synonyms: Protein-tyrosine kinase 6; SRC-related intestinal kinase; Ptk6; Sik
Species:
Source:
Cat. No.: HY-P75470
Purity: ≥ 85%, as determined by reducing SDS-PAGE.
Synonyms: Protein-tyrosine kinase 6; SRC-related intestinal kinase; Ptk6; Sik
Species:
Source:
- 1
- 2
-
-
Protocols
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!A suitable model is crucial in drug screening experiments. Organs can mimic the three-dimensional functional structure of internal organs, have similar spatial organization to corresponding organs, maintain some key characteristics, and reproduce some physiological functions. They are widely used for modeling and personalized drug screening physiological functions.2025-02-06
